Cassava Sciences (SAVA) Revenue & Revenue Breakdown
Cassava Sciences Revenue Highlights
Cassava Sciences Revenue by Period
Cassava Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $-1.80K | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | -100.00% |
| 2013-12-31 | $41.12M | 277.58% |
| 2012-12-31 | $10.89M | -5.17% |
| 2011-12-31 | $11.48M | -31.68% |
| 2010-12-31 | $16.81M | -18.26% |
| 2009-12-31 | $20.56M | -67.73% |
| 2008-12-31 | $63.73M | -3.42% |
| 2007-12-31 | $65.98M | 22.38% |
| 2006-12-31 | $53.92M | 961.38% |
| 2005-12-31 | $5.08M | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | -100.00% |
| 2002-12-31 | $114.00K | 100.00% |
| 2001-12-31 | - | -100.00% |
| 2000-12-31 | $1.00 | - |
| 1999-12-31 | $1.00 | - |
Cassava Sciences generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Cassava Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.35M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $-1.80K | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $-200.00 | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2019-09-30 | $104.00 | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | -100.00% |
| 2013-12-31 | $35.24M | 1700.00% |
| 2013-09-30 | $1.96M | -0.05% |
| 2013-06-30 | $1.96M | 0.05% |
| 2013-03-31 | $1.96M | -20.66% |
| 2012-12-31 | $2.47M | -9.43% |
| 2012-09-30 | $2.73M | 0.04% |
| 2012-06-30 | $2.72M | -8.38% |
| 2012-03-31 | $2.97M | 8.23% |
| 2011-12-31 | $2.75M | -0.07% |
| 2011-09-30 | $2.75M | -0.11% |
| 2011-06-30 | $2.75M | -14.96% |
| 2011-03-31 | $3.24M | -59.60% |
| 2010-12-31 | $8.01M | 176.65% |
| 2010-09-30 | $2.90M | 9.00% |
| 2010-06-30 | $2.66M | -18.25% |
| 2010-03-31 | $3.25M | -12.87% |
| 2009-12-31 | $3.73M | -0.90% |
| 2009-09-30 | $3.76M | -39.66% |
| 2009-06-30 | $6.24M | -8.76% |
| 2009-03-31 | $6.83M | -17.09% |
| 2008-12-31 | $8.24M | -72.79% |
| 2008-09-30 | $30.29M | 187.23% |
| 2008-06-30 | $10.55M | -27.95% |
| 2008-03-31 | $14.64M | 4.15% |
| 2007-12-31 | $14.06M | -11.09% |
| 2007-09-30 | $15.81M | - |
Cassava Sciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Cassava Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| EXEL | Exelixis | $1.83B | $478.06M |
| AXSM | Axsome Therapeutics | $270.60M | $87.17M |
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| MCRB | Seres Therapeutics | $126.33M | - |
| VIR | Vir Bio | $86.18M | $3.08M |
| CVAC | CureVac | $52.70M | $12.37M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| BTAI | BioXcel Therapeutics | $1.38M | $1.10M |
| VKTX | Viking Therapeutics | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| BIVI | BioVie | - | - |
| SAVA | Cassava Sciences | - | - |
| CGTX | Cognition Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| ANVS | Annovis Bio | - | - |
| AVXL | Anavex Life Sciences | - | - |
| INMB | INmune Bio | $-155.00K | - |
SAVA Revenue FAQ
What is Cassava Sciences’s yearly revenue?
Cassava Sciences's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $-1.8K, representing an increase of 100.00% compared to 2021. SAVA's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Cassava Sciences’s quarterly revenue?
Cassava Sciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). SAVA's quarterly revenue for Q4 2023 was $2.35M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Cassava Sciences’s revenue growth rate?
Cassava Sciences's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.